( MENAFN - PR Newswire) DALLAS, Texas , Nov. 7, 2024 /PRNewswire/ -- Naitive® Technologies Ltd., a population health company dedicated to developing innovative solutions in musculoskeletal care, today announced a strategic agreement with world-renowned Parvizi Surgical Innovation (PSI) to advance the development and clinical deployment of OsteoSightTM, a groundbreaking technology designed for the early identification of low bone mineral density.
This partnership aligns Naitive with some of the leading orthopedic surgeons in the world, giving them unique insights into the needs and demands of front-line healthcare providers. OsteoSightTM uses AI to opportunistically scan through millions of routine X-rays for evidence of low bone mineral density, an early warning sign of osteoporosis, and was granted FDA Breakthrough Device Designation last year. With PSI's renowned expertise in research, product development, and musculoskeletal care, this collaboration aims to expedite the validation and implementation of OsteoSightTM within clinical settings, making it more accessible to the millions of people with undiagnosed osteoporosis.
"Orthopedic surgeons are uniquely positioned to identify and address osteoporosis at an early stage, meaning more effective and accessible interventions for patients. We're excited to collaborate with Naitive, whose commitment to integrating clinical user feedback into their technology development is evident, and by ensuring OsteoSightTM aligns with clin.
